Leanova (Ethinylestradiol, Levonorgestrel)

Leanova, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

• Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential.
• Menstrual cycle regulation: helps achieve more predictable monthly bleeding patterns.
• Dysmenorrhea management: reduces severity of menstrual pain associated with primary dysmenorrhea.
• Acne improvement: may decrease androgen‑driven acne lesions in some users.
• Endometriosis symptom relief: can lessen pelvic pain associated with endometriosis.

• Ethinylestradiol and levonorgestrel bind to estrogen and progesterone receptors, respectively, suppressing the hypothalamic‑pituitary‑ovarian axis. This reduces the secretion of luteinizing hormone and follicle‑stimulating hormone, preventing follicular development and ovulation. The progestogenic component also thickens cervical mucus, creating a barrier to sperm, while inducing endometrial changes that are unfavorable for implantation. Together, these actions provide effective contraception when taken as directed each day.

Leanova may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild stomach upset often occurring early in treatment.
• Breast tenderness: temporary swelling or soreness of the breasts.
• Headache: mild to moderate headaches that usually resolve with continued use.
• Spotting or breakthrough bleeding: irregular light bleeding between periods.
• Weight fluctuation: slight increase or decrease in body weight.
• Mood changes: mild irritability or mood swings.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins, potentially leading to pulmonary embolism.
• Arterial thrombosis: clot formation in arteries, which may cause stroke or heart attack.
• Severe hypertension: sudden high blood pressure requiring medical attention.
• Hepatic adenoma: benign liver tumor associated with long‑term use.
• Gallbladder disease: formation of gallstones or inflammation.
• Anaphylaxis: rare severe allergic reaction with difficulty breathing or swelling.

Before prescribing Leanova, clinicians should evaluate several safety considerations to minimize risk.

• Cardiovascular assessment: review history of thromboembolic events, hypertension or smoking.
• Smoking status: avoid use in women over 35 who smoke cigarettes.
• Liver function: contraindicated in severe hepatic impairment; monitor liver enzymes.
• Blood pressure monitoring: check for hypertension during treatment.
• Medication review: assess for drugs that may reduce contraceptive efficacy.
• Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Leanova can interact with other medicines, altering its effectiveness or increasing adverse risk.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): markedly reduce contraceptive hormone levels.
• Rifampin and other rifamycins: decrease oral contraceptive efficacy.
• St. John’s wort: herbal inducer that may lead to contraceptive failure.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole): may increase hormone concentrations.
• Certain antibiotics (e.g., tetracycline, metronidazole): could slightly reduce effectiveness.
• Antidepressants (e.g., SSRIs): may enhance risk of mood‑related side effects.